Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10819
Title: | Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study | Authors: | Demirci, A. Alkış, N. Dane, F. Durnalı, A. Yazıcı, Ö.K. Rzayev, R. Kaya, S. |
Keywords: | breast cancer medical oncology pharmacy anthracycline aromatase inhibitor cyclophosphamide docetaxel fluorouracil gonadorelin associated peptide derivative tamoxifen trastuzumab gonadorelin adjuvant therapy adult Article cancer grading cancer patient cancer survival controlled study demography disease free survival early cancer female follow up hormone sensitivity human major clinical study multiple cycle treatment overall survival premenopause priority journal retrospective study survival time treatment duration Turkey (republic) breast tumor middle aged mortality oncology young adult Adult Breast Neoplasms Disease-Free Survival Female Gonadotropin-Releasing Hormone Humans Medical Oncology Middle Aged Retrospective Studies Young Adult |
Publisher: | Blackwell Publishing Ltd | Abstract: | Aim: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. Methods: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. Results: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1–87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4–12 months (Group A), 13–24 months (Group B) and ?25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 ± 30.3 (range, 4–188) months. The OS in patients ?35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000). Conclusion: There is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use. © 2017 John Wiley & Sons Australia, Ltd | URI: | https://hdl.handle.net/11499/10819 https://doi.org/10.1111/ajco.12685 |
ISSN: | 1743-7555 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
1
checked on Feb 24, 2024
WEB OF SCIENCETM
Citations
1
checked on Sep 24, 2024
Page view(s)
32
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.